MA09.03 Plasma Proteomics-based Models for Predicting Immunotherapy- and Chemotherapy-Related Toxicity in NSCLC Patients
Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Yehonatan Elon, Coren Lahav, Ben Yellin, R.R. Sullivan(Massachusetts General Hospital), David R. Gandara(University of California, Davis), M. Gottfried, J. Bar, Iris Kamer, Raya Leibowitz‐Amit(The University of Texas MD Anderson Cancer Center), Igor Puzanov(Roswell Park Comprehensive Cancer Center), P. Christopoulos(Hautklinik Heidelberg), M. Moskovitz(Rabin Medical Center), Alona Zer(Rambam Health Care Campus), Adva Levy‐Barda(Rabin Medical Center), Sarah Brown(University of Leeds), Gillian Price(Aberdeen Royal Infirmary), Michal Lotem(Hadassah Medical Center), Young Kwang Chae(Northwestern University), N. Reinmuth(Asklepios Fachklinikum Brandenburg), A. Agbarya(Bnai Zion Medical Center), M. Abu Amna(Emek Medical Center), Itamar Sela(Tel Aviv University), Adam Hassani(Freeman Hospital), T. Harkovsky, Michal Harel(Bifröst University), D. Carbone(The Ohio State University), Ina Koch(Asklepios Fachkliniken München-Gauting)
Cited by 0
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k